I didn't want to give specific timeframes. This is what I said:
A good outcome from the COVID ARDS trial could move us to $8.85 ballpark relatively quickly. As for the $17 valuation ... the market is forward-looking and it really comes down to timelines for commercialisation of Pediatric and Adult GVHD treatment ( these make up about 30% of the overall $17 valuation ). My perspective is that once revenues are coming in for Pediatric GVHD, the market will start to price in revenues for Adult GVHD.
- Risk-adjusted value @ $8.85 for Adult GVHD, Pediatric GVHD and COVID ARDS
(potential future target for this group @ $17)
Note - Advanced Heart Failure and Chronic Low Back Pain are not included in the $17 target and we have reports from trials expected around mid year.
- Forums
- ASX - By Stock
- MSB
- Tracking Valuations
Tracking Valuations, page-23
-
- There are more pages in this discussion • 300 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.32 |
Change
0.000(0.00%) |
Mkt cap ! $1.507B |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 9 | $1.34 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.29 | 8381 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 9 | 1.340 |
1 | 3773 | 1.325 |
5 | 34505 | 1.320 |
1 | 5850 | 1.315 |
3 | 15975 | 1.310 |
Price($) | Vol. | No. |
---|---|---|
1.280 | 9635 | 5 |
1.290 | 9378 | 2 |
1.310 | 5000 | 1 |
1.315 | 20000 | 1 |
1.320 | 35338 | 6 |
Last trade - 09.56am 01/11/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
Day chart unavailable